The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine  by Weinberger, Esther E. et al.
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Background:  Gene  vaccines  offer  attractive  rationales  for prophylactic  as  well  as therapeutic  treatments
of  type  I  allergies.  DNA  and mRNA  vaccines  have  been  shown  to prevent  from allergic  sensitization  and
to  counterbalance  established  allergic  immune  reactions.  Recent  advances  in  gene vaccine  manipulation
offer  additional  opportunities  for  modulation  of  T helper  cell proﬁles  by speciﬁc  targeting  of cellular
compartments.
Methods:  DNA  vaccines  encoding  the major  birch  pollen  allergen  Bet  v  1.0101  were  equipped  with  differ-
ent  leader  sequences  to shuttle  the antigen  to  lysosomes  (LIMP-II),  to  trigger  cellular  secretion  (hTPA),  or
to  induce  proteasomal  degradation  via  forced  ubiquitination  (ubi).  Mice  were pre-vaccinated  with these
constructs  and  the protective  efﬁcacy  was  tested  by  subcutaneous  Th2-promoting  challenges,  followed
by  allergen  inhalation.  IgG  antibody  subclass  distribution  and  allergen-speciﬁc  IgE as well  as  cytokine
proﬁles  from  re-stimulated  splenocytes  and  from  BALFs  were  assessed.  The  cellular  composition  of  BALFs,
and  lung  resistance  and compliance  were  determined.
Results: Immunization  with  all targeting  variants  protected  from  allergic  sensitization,  i.e. IgE  induc-
tion,  airway  hyperresponsiveness,  lung  inﬂammation,  and  systemic  and  local  Th2  cytokine  expression.
Surprisingly,  protection  did  not  clearly  correlate  with  the  induction  of  a  systemic  Th1  cytokine  proﬁle,
but rather  with  proliferating  CD4+  CD25+  FoxP3+  T regulatory  cells  in  splenocyte  cultures.  Targeting
the  allergen  to proteasomal  or lysosomal  degradation  severely  down-regulated  antibody  induction  after
vaccination,  while  T  cell  responses  remained  unaffected.  Although  secretion  of antigen  promoted  the
highest  numbers  of Th1  cells,  this  vaccine  type  was  the  least  efﬁcient  in suppressing  the  establishment
of  an  allergic  immune  response.
Conclusion:  This  comparative  analysis  highlights  the  modulatory  effect  of antigen  targeting  on the  result-
ing  immune  response,  with  a  special  emphasis  on prophylactic  anti-allergy  DNA vaccination.  Targeting
the  antigen  to proteasomal  or  lysosomal  degradation  reduces  the  availability  of  native  allergen,  thereby
rendering  the vaccine  hypoallergenic  without  compromising  efﬁcacy,  an  important  feature  for  a  thera-
peutic  setting.Abbreviations: AA, amino acid; AHR, airway hyperreactivity; APC, antigen
resenting cell; BAL, bronchoalveolar lavage; BALF, bronchoalveolar lavage ﬂuid;
IMPII, 20-amino-acid C-terminal tail of lysosomal integral membrane protein-II;
IT, speciﬁc immunotherapy; Th, T helper; tPA, human tissue plasminogen activator
eader peptide; Treg, T regulatory; Ubi, ubiquitin.
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1. Introduction
One of the unique features of gene vaccines is their potential
to design optimized immunization approaches speciﬁcally tailored
for a wide range of diseases including cancer [1], infectious diseases
[1,2], autoimmune diseases [3] and allergic disorders [4,5]. Since
their ﬁrst description in the early 1990s, substantial efforts have
been made to enhance the immunogenicity of gene vaccines and to
instruct the proper branch of the immune defense, depending on
the type of pathogen/disease. Among the numerous ways how to
modulate translation of antigens, are strategies to shuttle the anti-
gen of interest to different subcellular compartments (cytoplasm,
reserved.
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ndosomes/lysosomes [6–9]), to induce cellular secretion [10,11]
r cell membrane insertion [12], or guiding to protein-processing
achineries (proteasome [13–17], endosome/lysosome). All these
odiﬁcations are part of mechanisms that play an important role
n host-pathogen interactions and represent evolved strategies for
ptimizing immune responses.
Our working group has specialized on genetic vaccination
gainst allergy and we, as well as others, could provide evi-
ence that plasmid-encoded antigens trigger the induction of a
h1-balanced immune proﬁle [18–20] that is capable of counter-
alancing and protecting from allergic sensitization [21,22]. All
he mentioned approaches inﬂuence the immunogenicity and bal-
nce of humoral/cellular immunity; moreover, some of them act
n T-helper cell polarization (Th1, Th2, Th17, Treg). The latter
spect plays a crucial role in the development of both, protective
s well as therapeutic gene vaccination approaches against type I
llergy.
Here, we compared a compendium of DNA vaccine targeting
trategies (Fig. 1) on major birch pollen allergen Bet v 1.0101 (Bet)
peciﬁc allergy. DNA vaccines were constructed with the allergen
ene linked with sequences encoding the (i) human tissue plas-
inogen activator leader peptide (tPA), (ii) ubiquitin (Ubi), (iii) the
0AA C-terminal tail of the lysosomal integral membrane protein-II
LIMPII), or (iv) left without modiﬁcation. The tPA leader sequence
ncodes a strong signal peptide for protein secretion thus medi-
ting the release of antigen into the extracellular space. Secreted
ntigen can be taken up and processed by APC (Fig. 1[1a]), result-
ng in presentation of antigenic peptides on MHC-II. Nevertheless,
 small part will be presented on MHC-I molecules by a mecha-
ism which is called cross-priming [14]. In contrast, Bet lacking
 secretory signal sequence, is expressed as cytoplasmic protein
Fig. 1[1b]) and will be presented on MHC-I per default. Like with
rosspriming, which ensures antigen delivery from the MHC-II
athway to MHC-I, mechanisms have evolved which enable the
xchange of molecules from MHC-I to MHC-II pathways. These
ig. 1. DNA vaccine-targeting strategies. After entering the nucleus (1), the plasmid DNA is
a)  The 5 ‘attached tPA signal sequence leads to shuttling of the vaccine-derived Bet to the e
nformation is translated into the cytosol, leading to vaccine-derived endogenous peptid
rotein into the polyubiquitination pathway thereby speciﬁcally targeting peptides to MH
ysosomes that facilitate peptide presentation on MHC-II. Along with direct transfection 
ecreted vaccine-derived antigens, that have been shed from transfected cells, enforce pe
ell-associated exogenous antigens, e.g. by engulfment of transfected and apoptotic cellse 31 (2013) 6113– 6121
mechanisms include shedding of native protein from transfected
cells by a still unknown mechanism, which was described as
“leakage” (Fig. 1[2]), release of antigen within apoptotic vesicles
(immune apoptosis), and transport of cytosolic material into the
MHC-II pathway via autophagy (Fig. 1[3]) [23,24].
Ubiquitination shuttles the antigen into the polyubiquitina-
tion pathway (Fig. 1[1c]), thereby speciﬁcally promoting the
presentation of antigenic peptides on MHC-I [17]. In contrast,
LIMPII peptide attachment facilitates the antigenic transport from
the cytosol to lysosomes (Fig. 1[1d]), thus allowing MHC-II presen-
tation [6].
Our data indicate that targeting has a substantial effect on the
strength of humoral immunity, and all targeting variants demon-
strated a Th1-bias. Furthermore, targeting proved to be a valuable
approach to develop new rationales for optimized anti-allergic
gene vaccines.
2. Materials and methods
2.1.1. Mice, treatment schedules and serology
Female, 6–10 week-old BALB/c mice were obtained from Charles
River Laboratories (Sulzfeld, Germany). All animal experiments
were conducted according to local guidelines approved by the
Austrian Ministry of Science and in accordance with EU Directive
2010/63/EU.
To assess humoral/cellular proﬁles after vaccination, BALB/c
mice (n = 5) were immunized intradermally (i.d.) with plasmid DNA
encoding Bet, Ubi-Bet, tPA-Bet or Bet-LIMPII on days 0, 7 and 14.
100 g plasmid DNA in 200 l sterile PBS were i.d. injected at 6–8
spots on the back of isoﬂurane-anesthetized animals. On  day 49,
blood samples were taken and splenocytes were prepared (Fig. 2A).
To analyze the protective efﬁcacy of the vaccine on alum-induced
allergic sensitization (Fig. 3A), vaccinations on days 0, 6, and 13
were performed as described above. On days 27, 41 and 48, mice
 transcribed and differentially processed, depending on the respective modiﬁcation.
xterior of transfected cells via the Golgi apparatus, while (b) the unmodiﬁed genetic
e presentation on MHC-I molecules. (c) Ubiquitin attachment feeds the translated
C-I. (d) In contrast, LIMPII peptide attachment promotes the antigenic transport to
of both, resident immunocompetent as well as somatic cells, (2) the engulfment of
ptide processing within the endocytic pathway, or, (3) MHC-I cross-presentation of
, are potential modes of neoantigen presentation to the immune system.
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Fig. 2. Bet-speciﬁc humoral and cellular immune responses upon i.d. genetic vaccination. (A) Schematic overview of the experimental schedule. Mice were i.d. immunized
(triangle) in weekly intervals and blood samples (drop) were taken at day 49 after initial immunization. Bet-speciﬁc IgG1 (B) and IgG2a (C) antibody levels 5 weeks after the
ﬁnal  vaccination were determined by luminescence-based ELISA. Depicted are results at a ﬁnal sera dilution of 1:1000. (D) Proliferation of in vitro Bet re-stimulated splenocytes
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P  < 0.05; **P < 0.01; ***P < 0.001 compared to naïve animals or as indicated.
ere sensitized by two  subcutaneous (s.c.) injections with 5 g
f recBet v 1.0101 (Biomay AG, Vienna, Austria) in 100 L PBS
mulsiﬁed in 100 L Al(OH)3 (Alu–Gel–S, Serva). On days 57–59,
ice received airway challenges by exposure to aerosolized Bet
rotein in PBS (1 mg/mL) using a jet nebulizer (PARIBOY®LCplus;
ARI GmbH, Starnberg, Germany). 24 h later, animals were sac-
iﬁced after invasive lung measurement of lung functions, and
ronchoalveolar lavages (BALs) were collected. Antigen-speciﬁc
erum IgG1, IgG2a, and IgE were determined by ELISA or RBL assay,
nd cell-bound IgE was detected by a basophil activation test (BAT).
 detailed description of these and additional methods can be found
n supplementary materials online.
. Statistical analysisStatistical signiﬁcance between groups was assessed by Stu-
ents t-test and correlations were assessed by Spearman’s Rank
orrelation using GraphPad Prism 5.01.SFU) was  determined by ELISPOT assay (E). Data are shown as means ± SEM (n = 3).
4. Results
4.1. In vitro expression of targeting variants
To assess the targeting efﬁcacy of vaccine-derived antigen to
different subcellular compartments, BHK-21 cells were transfected
in vitro with plasmid DNA encoding Bet, eGFP or the targeting
versions of these molecules (tPA-Bet, tPA-GFP, Ubi-Bet, Ubi-GFP,
Bet-LIMPII or GFP-LIMPII). Secretion (tPA-GFP) as well as forced
proteasomal degradation (Ubi-GFP) of the gene products signiﬁ-
cantly reduced the cellular mean ﬂuorescence intensity (MFI) of
eGFP compared to the unmodiﬁed version (Suppl. Fig. 2A). Attach-
ment of the LIMPII peptide increased the MFI, surprisingly, as
endosomal targeting should reduce the ﬂuorescence of eGFP by
both – proteolytical degradation as well as lowered pH.
Western blot analysis of Bet targeting construct transfections
conﬁrmed cytosolic Bet protein expression at 17.6 kDa, Bet-LIMPII
at 19.8 kDa and tPA-Bet at 20.7 kDa (Suppl. Fig. 2B). tPA-Bet
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Fig. 3. Humoral immune proﬁle after vaccination and sensitization. (A) Schematic overview of the experimental schedule. Mice were i.d. immunized (black triangle)
three  times in weekly intervals and sensitized (gray triangle) for three times, before blood samples (drop) were taken at day 56 after initial immunization. After three
consecutive allergen inhalation challenges (gray trapezium), lung resistance/compliance was  measured and mice were sacriﬁced (cross). Bet-speciﬁc IgG1 (B), IgG2a (C) and
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D).  For BAT, whole blood was  ex vivo stimulated with Bet protein. Data are displ
asophils. Data are shown as means ± SEM (n = 6). *P < 0.05; **P  < 0.01; ***P < 0.001 c
ontained two putative signal peptide cleavage sites as predicted
y the SignalP 4.0 algorithm [25], located between AA22-23 and
A28-29, resulting in a molecular weight (MW)  of 18.46 kDa or
7.9 kDa for Bet protein without tPA leader, respectively. Analy-
is of the supernatant of transfected cells conﬁrmed successful Bet
rotein secretion (Suppl. Fig. 2B).
Ubiquitinylated Bet protein (Ubi-Bet) displayed as two bands
26.4 kDa and 17.6 kDa), representing Bet protein with and without
biquitin, although we introduced a Gly76–Ala76 point mutation
o diminish the cleavage rate of the fusion protein [26]. Successful
olyubiquitination was observed as bands of increasing MW (Suppl.
ig. 2B).
.2. Selective targeting of DNA vaccine-derived Bet v 1.0101 to
pecialized subcellular compartments modulates the
h1-polarized immune response
Modulation of the Bet-speciﬁc humoral and cellular immu-
ity was addressed using the experimental design shown inence-based ELISA (IgG1, IgG2a) or RBL assay (IgE). Control animals received sham
otein sensitization. Sera were diluted 1:1000 for ELISA (B and C) and 1:50 for RBL
s fold induction of up-regulated CD200R of antigen-stimulated vs. un-stimulated
red to control group or as indicated.
Fig. 2A. Vaccination of BALB/c mice with plasmid DNA encod-
ing Bet was characterized by substantial humoral and cellular
memory immune responses [27]. High titers of Bet-speciﬁc IgG1
and the induction of IgG2a, as well as IFN- producing spleno-
cytes upon in vitro Bet protein re-stimulation, both of which are
indicative for Th1 immunity, could be detected 5 weeks after
i.d. application (Fig. 2B, C and E). Ubiquitination of Bet (Ubi-
Bet) abrogated antibody responses due to immediate epitope
destruction, but still induced a potent Th1-polarized immune
response (Fig. 2B–E). A similar effect was  observed for lyso-
somal targeting using Bet-LIMPII. Secretion of Bet (tPA-Bet)
led to comparable levels of IgG1/IgG2a as observed for Bet-
vaccinated animals (Fig. 2B and C), but the cellular response
was signiﬁcantly enhanced (Fig. 2D and E). This is consis-
tent with published data showing that tPA-mediated secretion
enhances immunogenicity against plasmid DNA-derived proteins
[11]. Therefore, we  next tested the capacity of Bet targeting
variants to protect from alum-induced Bet-speciﬁc sensitization
(Fig. 3A).
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.3. Bet targeting variants protect from induction of IgE by
llergic sensitization with recombinant Bet v 1.0101
Sham immunized (mock) and non-immunized control ani-
als (control) displayed the typical picture of sensitization with
lum adsorbed allergen, including high IgG1 and IgE titers as
ell as the absence of IgG2a (Fig. 3B–E). Pre-vaccination with
argeting variants resulted in the reduction of Bet-speciﬁc IgG1
Fig. 3B), boosting of IgG2a (Fig. 3C) and the potent blockage of Bet-
peciﬁc IgE induction (Fig. 3D). Flow cytometric analysis of blood
asophils via basophil activation test (BAT) conﬁrmed a reduced Bet
rotein-induced activation of basophils in tPA-Bet and Bet-LIMPII
re-vaccinated animals (Fig. 3E). Noteworthy, while the RBL assay
s a direct read out of allergen-speciﬁc IgE and non-cell bound IgGs
re washed away before addition of antigen, the stimulation of
asophils during the basophil activation test takes place in whole
lood samples. Therefore, blocking IgGs can compete for antigen
inding sites and interfere with IgE cross-linking on basophils.
o determine, whether immunization with our Bet construct also
nduced blocking antibodies, we performed a BAT in the presence or
ig. 4. Cellular proliferation and cytokine responses of Bet re-stimulated splenocytes fro
nimals after sensitization. (A) Numbers of IL-4 and IFN- secreting splenocytes (ELISP
timulated splenocytes (FlowCytomix) were measured. (H) CFSE-based analysis of prolif
ell  as (I) the percentage of CD25+ Foxp3+ of proliferating CD4+ T cells are displayed. Dat
o  control group or as indicated.e 31 (2013) 6113– 6121 6117
absence of antibody containing plasma. Indeed, removal of plasma
from PBMCs increased activation of basophils from Bet immunized
mice. These data indicate the presence of blocking antibodies in
plasma of Bet vaccinated mice, but not in sensitization controls
(Suppl. Fig. 3).
4.4. Pre-vaccination with Bet targeting variants speciﬁcally
suppresses Th2-associated cytokine production and increases the
percentage of FoxP3+ CD25+ cells in Bet re-stimulated
proliferating CD4+ T cells
Analysis of Bet re-stimulated splenocytes revealed a downreg-
ulation of Th2 immune responses in all pre-vaccinated groups,
indicated by drastically reduced IL-4 spot forming units (SFU)
(Fig. 4A) as well as IL-5 (Fig. 4B) and IL-13 (Fig. 4D) in the
supernatants of splenocytes. tPA-Bet was less effective in IL-13
suppression than the other targeting variants, although increased
numbers of IFN- producing splenocytes could be detected after
vaccination (Fig. 2E) and sensitization (Fig. 4A). Noteworthy, the
number of IFN--producing cells primed by pre-vaccination for Bet
m pre-vaccinated animals, sham immunized (mock), or non-immunized (control)
OT) as well as an extensive panel of other cytokines (B–G) released from Bet re-
erating CD4+ T cells, given as fraction of proliferating to non-proliferating cells as
a are shown as means ± SEM (n = 6 or 3). *P < 0.05; **P < 0.01; ***P < 0.001 compared
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Fig. 5. Airway hyperresponsiveness and BAL analysis of Bet pre-vaccinated, sham-immunized (mock), or non-immunized (control) animals following sensitization and
a istanc
v ytomi
3 up or 
a
i
c
T
a
i
(
e
t
r
s
l
e
c
(
4
a
uirway  challenge. AHR was assessed after Bet inhalation by measurement of lung res
ia  ﬂow cytometric analysis and BALF cytokine levels (H–J) were assessed by FlowC
).  AUC, area under curve; *P < 0.05; **P  < 0.01; ***P < 0.001 compared to control gro
nd the other targeting variants (Ubi-Bet and Bet-LIMPII) were min-
mally boosted by sensitization and did not differ from mock or
ontrol (Fig. 4A).
Pre-vaccination also suppressed IL-22 (Fig. 4C), indicative for
h17/Th22 cells [28] that may  contribute to the early onset of
llergic lung inﬂammation. Again, tPA-Bet was less effective in
nhibiting IL-22 production. Pre-vaccination also inhibited IL-6
Fig. 4F), another cytokine contributing to enhanced Th17 differ-
ntiation [29].
Flow cytometric analysis of CFSE-stained splenocytes showed
hat pre-vaccination diminished the proliferative potential of Bet
e-stimulated CD4+ T cells (Fig. 4H) a feature associated with
uccessful plasmid DNA vaccination [14]. Further analysis of pro-
iferating CD4+ T cells in splenocyte cultures revealed a strongly
levated percentage of CD25+ FoxP3+ cells within this pool (Fig. 4I),
ompared to control and mock, but decreased levels of IL-10
Fig. 4E).
.5. Bet targeting variants suppress lung inﬂammation and
irway hyperreactivity
Lung inﬂammation and airway hyperreactivity (AHR) induced
pon consecutive Bet protein inhalation were analyzed 24 he (A) and dynamic compliance (B). Cellular composition of BAL (C–G) was analyzed
x. Both assays are presented as individual data points and/or means ± SEM (n = 6 or
as indicated.
after the last allergen challenge by ﬂow cytometric analysis and
invasive lung measurement. Pre-vaccination with Bet abrogated
AHR reactions, as measured by airway resistance (Fig. 5A) and
compliance (Fig. 5B). Ubi-Bet and Bet-LIMPII were slightly less
effective in reducing AHR parameters, while tPA-Bet completely
failed to provide protection. Nevertheless, collected BALFs showed
signiﬁcantly reduced numbers of inﬁltrating leukocytes (Fig. 5C),
especially eosinophils (Fig. 5D), in all pre-vaccinated groups. The
MHC-I and MHC-II targeting variants turned out to be most effec-
tive in inhibiting CD4+ and CD8+ lymphocytic inﬁltration, while
unmodiﬁed Bet and tPA-Bet could only reduce the inﬂux of CD4+
T cells (Fig. 5E). Bet-LIMPII was  also the most effective variant in
suppressing neutrophils (Fig. 5F) and macrophages (Fig. 5G). Cor-
responding to the total numbers of CD4+ T cells, also the number of
CD4+ FoxP3+ cells was  diminished, however in contrast to the data
from re-stimulated splenocytes (Fig. 4I) the percentage of FoxP3+
T helper cells was  similar in all groups (Bet 14.5 ± 1.3%, Ubi-Bet
15.6 ± 1.4%, tPA-Bet 15.1 ± 0.96%, Bet-LIMPII 13.1 ± 1.1%, control
15.5 ± 3.2%, mock 13.8 ± 0.7%).In line with eosinophil and lymphocyte data, Th2-associated
cytokines such as IL-4, IL-5, and IL-13 were also reduced in all vac-
cinated groups (Fig. 5H–J). Th1 (IFN-, IL-2, TNF-), Treg (IL-10)
and Th17/Th22 (IL-17, IL-22) associated cytokines as well as, IL-1,
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L-21, and IL-27 did not differ among all groups or were beyond
etection limit (IL-17).
To conﬁrm that the suppression of cellular inﬁltrates in BALFs
eﬂected the lung tissue in situ, we exemplarily compared the cellu-
ar composition of collagenase digests of the right lung lobes of Bet
mmunized mice compared to sensitization controls and naïve mice
n a separate experiment. As shown in supplementary Fig. S4, vac-
ination suppressed the numbers of tissue eosinophils (Suppl. Fig.
B) as well as alveolar macrophages (Suppl. Fig. 4D), and there was a
igh correlation between eosinophil numbers from BALF and tissue
igest (Suppl. Fig. 4E, P < 0.0001). We  also addressed the question,
hether the suppression of airway inﬂammation was  associated
ith a change in GITR-L expression on antigen presenting cells
n the lung. When staining with CD11b and CD11c we  observed
D11bhigh CD11clow cells (Suppl. Fig. 5A, upper left quadrant) that
orresponded to neutrophils, a population of CD11bhigh CD11chigh
ells (Suppl. Fig. 5A, upper right quadrant) that most likely repre-
ented freshly recruited alveolar macrophages [30], and CD11bmed
D11chigh cells (Suppl. Fig. 5A, lower right quadrant) that were
robably pulmonary DCs. Sensitization induced a strong inﬂux
nd/or maturation of CD11bhigh CD11chigh alveolar macrophages
Suppl. Fig. 5B) as described in pneumococcal infection [30], while
he number of pulmonary DCs was only slightly enhanced (Suppl.
ig. 5C). While GITR-L expression on pulmonary DCs was similar
o naïve mice (Suppl. Fig. 5E), alveolar macrophages in sensitized
ice, but not in Bet pre-vaccinated mice, showed an upregulation
f surface GITR-L (Suppl. Fig. 5D).
The left lung lobes of the same mice were also analyzed histolog-
cally on HE and PAS stained parafﬁn sections. Overall, there was
nly weak to moderate tissue inﬂammation (Suppl. Fig. 6); how-
ver, pre-vaccination with Bet reduced lung pathology compared to
ensitization controls. PAS staining revealed no mucus-producing
oblet cells in any of the samples (not shown).
. Discussion
Genetic immunization harbors great potential for the develop-
ent of human vaccines, as demonstrated by numerous preclinical
nd clinical studies treating a variety of diseases ranging from
iral infections to cancer. The potential to induce Th1-balanced
mmunity against encoded antigens renders gene vaccines inter-
sting candidates, particularly for prophylactic allergy vaccination.
uch an approach demands careful selection of allergens to
e included and close consideration of the timing of interven-
ion [31]. Recently, several biomarkers have been established in
rder to predict the risk for sensitizations to allergens [32–34],
hich may  allow for prophylactic allergy treatment in genetically
redisposed, presymptomatic individuals. Clearly, prophylactic
reatment requires highest safety standards and thorough knowl-
dge of immunomodulatory consequences. In the current study
e provide a comprehensive comparison of DNA vaccine vector
odiﬁcations feeding the encoded allergen into selected sub-
ellular compartments (Suppl. Fig. 1), thereby modulating the
esulting immune response. In line with previous publications we
ould demonstrate effective targeting of cellular compartments by
ppending the respective leader sequences (Suppl. Fig. 2), except
f LIMPII. In contrast to Rodriguez et al. [7], in our hands, BHK-
1 transfections using GFP-LIMPII did not result in co-localization
f the GFP signal with lysosomal markers (data not shown) or
ysosomal degradation (Suppl. Fig. 2). However, Bet-LIMPII dis-
layed a severely reduced capacity to induce antibody-responses
Fig. 2B and C), indicating a more potent intracellular degrada-
ion compared to the cytosolic (Bet) or the secreted Bet (tPA-Bet).
herefore, the effect of the LIMPII targeting sequence may  be
ntigen-dependent.e 31 (2013) 6113– 6121 6119
In vivo evaluation of the anti-allergic capacity of Bet targeting
variants in a mouse model of allergy revealed potent regulatory
potential for the induction of cellular and humoral immunity. Par-
ticularly, targeting of proteolytical compartments (lysosome) or
machineries (proteasome) proved to be a limiting factor for the
induction of humoral immunity (Fig. 2B and C). This may provide
a general approach to reduce the amount of protein in its native
conformation, i.e. the availability of B cell epitopes, thereby reduc-
ing the risk of unwanted antigen-antibody complex-mediated side
reactions upon vaccination. Simultaneously, immunogenicity on T
cell level was retained (Fig. 2E and F). All constructs maintained
their ability to block IgE induction upon sensitization (Fig. 3D), a
necessary prerequisite for anti-allergy DNA vaccination.
We and others have previously demonstrated that the anti-
allergic capacity of plasmid DNA and mRNA vaccines strongly
correlates with promotion of Th1-biased responses, and is depend-
ent on IFN- and in part on IL-12 [35–37]. On the other hand,
induction of T regulatory cells via nucleic acid vaccination has also
been shown [38]. Although in our current work, all targeted vac-
cines induced Th1-biased immune responses (Fig. 2C and E), the
Th1 memory responses after sensitization (Fig. 4A) did not corre-
late with suppression of Th2 immunity (Fig. 4A, B and D) and lung
pathology (Fig. 5). Although guiding the antigen to the secretory
pathway (hTPA) led to enhanced Th1 immunity, this group showed
the weakest suppression of systemic and local Th2 cytokines and
no protection from allergen-induced AHR. Notably, also sham-
immunized and non-immunized control mice displayed elevated
numbers of IFN- secreting T cells after sensitization (Fig. 4A).
Recent publications highlighted the induction of IFN- producing
CD8+ T cells by alum-absorbed protein [39,40] along with Th2-
polarized CD4+ T cells, substantiating our observation of IFN-
production in ELISPOT for these experimental groups. Interestingly,
tPA-Bet vaccinated mice also displayed lower numbers of splenic
CD25+ FoxP3+ regulatory T cells compared to the other DNA vacci-
nated groups (Fig. 4I), indicating the importance of this cell type in
our model. The percentage of CD25+ FoxP3+ T cells inversely cor-
related with the amount of secreted IL-2 in culture supernatants
(P < 0.001), which may  indicate competition for IL-2 secreted by
responder T cells, a mechanism by which Tregs can also exert their
suppressive potential [41]. Although IL-10 is an important effec-
tor cytokine secreted by Treg cells for active suppression [42], in
our model IL-10 secretion was  reduced in pre-vaccinated animals
(Fig. 4E). Indeed, the secretion of IL-10 by re-stimulated spleno-
cytes clearly correlated with the secretion of IL-4, IL-5, and IL-13
(P < 0.0001) suggesting that it was  Th2 cell-derived. Pre-vaccination
also suppressed IL-22 secretion, an indicator of Th17 polarization.
Although we could not detect IL-17, sensitization can lead to the
generation of IL-22 secreting Th17 cells via the inﬂammasome/IL-
1 axis [43].
Allergen-speciﬁc blocking IgG antibodies, which occupy the
binding sites for IgE on allergens and control basophil activation
via low-afﬁnity IgG receptors [44] represent another mechanism of
successful immune therapy [45,46]. Production of allergen-speciﬁc
blocking IgG has been previously demonstrated following immu-
nization with trimers of hypoallergenic fragments of Bet v 1 [47] or
a mimotope gene vaccine [48]. Here, DNA vaccination induced high
levels of allergen-speciﬁc IgG2a after sensitization, but suppressed
IgG1 (Fig. 3B and C). Removal of plasma from PBMCs during the
basophil activation test increased the reactivity of basophils in Bet
pre-vaccinated mice, but not in sensitization controls (Suppl. Fig.
3), indicating the blocking capacity of the induced antibodies. How-
ever, the exact mechanism of how DNA vaccine-induced antibodies
exert their blocking effect (via low-afﬁninity IgG receptor mediated
suppression or inhibition of IgE binding), remains to be determined.
Aerosol challenge of sensitized mice induced AHR and an
inﬂux of leukocytes (mainly eosinophils and T cells) into the lung
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Fig. 5). Targeting the antigen to either MHC-I (ubi-Bet) or MHC-
I (Bet-LIMPII) proved to be especially effective in suppressing
ung recruitment of CD4+ and CD8+ T cells as well as neutrophils,
nd in the case of Bet-LIMPII, also macrophages. Sensitization
nduced a clearly Th2-biased cytokine milieu in the lung, which
as efﬁciently suppressed by pre-vaccination with the DNA vac-
ines, without inducing detrimental effects or changes in the Th1
r Th17 cytokine proﬁle. Interestingly, alveolar macrophages from
ensitized, but not from Bet vaccinated mice showed enhanced
xpression of GITR-L (Suppl. Fig. 5). GITR signaling has been impli-
ated in both, expansion of Treg as well as effector T cells in a
ontext-dependent manner [49]. It has been recently shown, that
uring Th2-polarized airway inﬂammation GITR-L was upregu-
ated on lung epithelial cells which in turn lost their potential to
uppress local T-cell responses [50]. GITR-L has also been shown
o be upregulated on APC during inﬂammatory processes and to
rive inﬂammation by expansion of effector T cells [51]. Neverthe-
ess, further experiments will be necessary to elucidate the role of
lveolar macrophages and GITR-L expression in the initiation and
rogression of Th2 airway inﬂammation.
. Conclusions
Although DNA vaccines can prime Th1-biased immune
esponses and their anti-allergic mechanism has been clearly asso-
iated with the induction of IFN-, we and others have also
emonstrated their potential to induce regulatory T cell responses.
ere we show that protection from allergic sensitization and lung
nﬂammation can be achieved without dominant Th1-priming on
he systemic (spleen) or local (lung) level, presumably through the
ntigen-driven expansion of CD25+ FoxP3+ Treg cells. Targeting the
ntigen to proteasomal or lysosomal degradation was especially
otent in reducing inﬂammatory inﬁltrates in BAL and simulta-
eously rendered the vaccine hypoallergenic. In contrast, active
ecretion from transfected cells proved deleterious on the vaccine‘s
rotective efﬁcacy. The acquired data will therefore help to con-
truct tailor-made anti-allergy vaccines with increased beneﬁt/risk
atios.
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